Jaguar Health Reports Mixed Financial Results for 2025

Jaguar Health, Inc. has announced a 5% increase in net revenue for Q4 2025, raising approximately $3.2 million. This growth from the previous quarter contrasts with an 8% drop from Q4 2024's revenue. A significant boost came from a new U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1, yielding $16 million and potential future payments totaling $20 million.

Despite these gains, Jaguar faced challenges with a net loss of $53.6 million for 2025, a 28.2% increase from 2024. Elevated expenses in R&D and sales, as well as an impairment loss, contributed to this deficit. The company plans to appeal a Nasdaq noncompliance determination, affecting its stock listing. An investor webcast is scheduled for further discussion.